Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma

This phase 3 randomized controlled trial evaluated pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in a population of 158 Chinese adults with advanced and/or unresectable biliary tract carcinoma. The study setting was China, and the follow-up duration was 29.2 months. Primary outcomes focused on overall survival, while secondary outcomes were not reported. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. Funding or conflicts of interest were not reported.

The main results regarding overall survival were not reported in the available data. Consequently, no specific survival benefit or hazard ratios can be stated based on the provided information. The absence of reported safety metrics prevents a full assessment of the treatment's tolerability profile in this specific population.

Key limitations include the small sample size of 158 participants and the lack of reported primary and secondary outcome data. Practice relevance was not reported, and causality notes were not provided. The certainty of the findings is limited by the incomplete reporting of critical efficacy and safety endpoints. Clinicians should interpret these findings with caution due to the missing data on overall survival and adverse events.